ALK B ALK-ABELLO A/S

Management change at ALK

Management change at ALK

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Søren Jelert, Executive Vice President, CFO and member of the Board of Management, has decided to resign his position to join a company in another sector and will expectedly leave ALK on 31 May 2023.

Chairman of the Board of Directors, Anders Hedegaard, and President & CEO, Carsten Hellmann said: "We would like to offer our sincere thanks to Søren for his pivotal role in ALK's transformation over the past five years. We wish him the best of luck in his future career.”

A search for a new CFO has been initiated.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Jeppe Ilkjær, mobile

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at .

Attachment



EN
30/11/2022

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation til præsentation af ALK’s årsrapport for 2025 fredag den 20...

Invitation til præsentation af ALK’s årsrapport for 2025 fredag den 20. februar 2026 ALK (ALKB:DC / OMX: ALK B) offentliggør sin årsrapport for 2025 om morgenen fredag den 20. februar 2026. ALK afholder senere samme dag kl. 13.30 (CET) en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR-chef.  Live audio-webcast Mødet audiocastes live på , hvor genafspilning af præsentationen også vil vær...

February 13, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s annual report 2025 on Friday, ...

Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026 ALK (ALKB:DC / OMX: ALK B) will publish its annual report for 2025 in the morning on Friday, 20 February 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.  Live audio webcast The meeting will be audio webcasted live and be availab...

February 13, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK modtager anbefaling om godkendelse af EURneffy® 1 mg: En nålefri a...

ALK modtager anbefaling om godkendelse af EURneffy® 1 mg: En nålefri anafylaksibehandling til børn Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at Det Europæiske Lægemiddelagenturs komite for godkendelse af medicin til mennesker (Committee for Medicinal Products for Human Use, ‘CHMP’) har vedtaget at anbefale en godkendelse af adrenalinnæsesprayen EURneffy® 1 mg (varemærket for neffy® i EU)  til akutbehandling af allergiske reaktioner (anafylaksi) forårsaget af insektstik eller -bid, fødevarer, medicinske produkter og andre allergener samt idiopatisk eller træningsinducer...

January 29, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK receives positive recommendation for EURneffy® 1 mg: A needle-free...

ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’) of the European Medicines Agency has adopted a positive opinion recommending the granting of the marketing authorisation for EURneffy® (the trade name for neffy® in the EU) to include a 1 mg nasal adrenaline spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as wel...

January 29, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in...

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco ALK (ALKB:DC / OMX: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to give a company presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, 15 January 2026, at 9.45 AM PST / 12.45 PM EST / 6.45 PM CET. Representatives of the company will be available for meetings at the conference. ALK-Abelló A/S For further information, please contact: Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel....

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch